VÍTOVEC, Jiří, Lenka ŠPINAROVÁ and Jindřich ŠPINAR. Studie VERTIS‑CV (VERTIS-CV study). Remedia. Praha: Medical Tribune CZ, s.r.o., 2021, vol. 31, No 2, p. 154-155. ISSN 0862-8947.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Studie VERTIS‑CV
Name (in English) VERTIS-CV study
Authors VÍTOVEC, Jiří (203 Czech Republic, guarantor, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution) and Jindřich ŠPINAR (203 Czech Republic, belonging to the institution).
Edition Remedia, Praha, Medical Tribune CZ, s.r.o. 2021, 0862-8947.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/21:00124450
Organization unit Faculty of Medicine
Keywords (in Czech) VERTIS‑CV
Keywords in English VERTIS‑CV
Tags rivok
Tags Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 24/3/2022 08:45.
Abstract
Studie VERTIS‑CV testovala účinnost inhibitoru sodíko‑glukózového kotransportéru 2 (SGLT2i) ertugliflozinu, který je indikován jako perorální antidiabetikum.
Abstract (in English)
The VERTIS-CV study tested the efficacy of the sodium-glucose cotransporter 2 (SGLT2i) inhibitor ertugliflozin, which is indicated as an oral antidiabetic agent.
PrintDisplayed: 17/8/2024 03:23